-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Suvecaltamide Hydrochloride in Absence Seizure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Suvecaltamide Hydrochloride in Absence Seizure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Suvecaltamide Hydrochloride in Absence Seizure Drug Details: JZP-385 (CX-8998) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Triple-Negative Breast Cancer (TNBC) Drug Details: Lurbinectedin (Zepzelca)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Metastatic Biliary Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Metastatic Biliary Tract Cancer Drug Details: Lurbinectedin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GWP-42006 in Partial Seizure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GWP-42006 in Partial Seizure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GWP-42006 in Partial Seizure Drug Details: GWP-42006 (CBDV, cannabidivarin) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cannabidiol in Epileptic Encephalopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cannabidiol in Epileptic Encephalopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cannabidiol in Epileptic Encephalopathy Drug Details: Cannabidiol (Epidiolex , Epidyolex) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tremelimumab in Dysgerminoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tremelimumab in Dysgerminoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tremelimumab in Dysgerminoma Drug Details: Tremelimumab (Imjudo) is a human monoclonal monospecific...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cytarabine Hydrochloride + Daunorubicin Hydrochloride) in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cytarabine Hydrochloride + Daunorubicin Hydrochloride) in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cytarabine Hydrochloride...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Zanidatamab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanidatamab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanidatamab in Non-Small Cell Lung Cancer Drug Details: Zanidatamab is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanidatamab in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanidatamab in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanidatamab in Adenocarcinoma Of The Gastroesophageal Junction Drug...